MCID: PNC041
MIFTS: 51

Pancreatic Ductal Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

MalaCards integrated aliases for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 12 15 17 72
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 50 C9120
UMLS 72 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to pancreatic cancer and cholangiocarcinoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Ductal Adenocarcinoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Hyaluronic acid and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and t cells.

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 33.5 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTTIP
2 cholangiocarcinoma 31.7 UCA1 MIR21 MALAT1 H19 DAPK1 AFAP1-AS1
3 lung cancer susceptibility 3 31.4 MIR31HG MALAT1 HOTAIR H19 AFAP1-AS1
4 kidney cancer 31.3 PVT1 MIR21 MALAT1 HOTAIR H19
5 pituitary adenoma 31.2 MALAT1 HOTAIR H19
6 gastrointestinal system cancer 31.1 MALAT1 HOTAIR H19
7 osteogenic sarcoma 31.1 UCA1 PVT1 MALAT1 HOTTIP HOTAIR H19
8 small cell cancer of the lung 31.0 MIR21 MALAT1 HOTTIP HOTAIR
9 glioblastoma 31.0 MIR21 MALAT1 HOTAIRM1 HOTAIR H19
10 gallbladder cancer 31.0 UCA1 MALAT1 HOTAIR H19 AFAP1-AS1
11 renal cell carcinoma, nonpapillary 30.9 UCA1 PVT1 MALAT1 HOTAIR H19
12 esophageal cancer 30.9 UCA1 PVT1 MIR21 MALAT1 HOTTIP HOTAIR
13 prostate cancer 30.9 UCA1 PVT1 MIR21 MALAT1 HOTTIP HOTAIR
14 leukemia, acute myeloid 30.8 UCA1 MIR21 MIR155 MALAT1 HOTAIRM1 HOTAIR
15 nasopharyngeal carcinoma 30.8 PVT1 MALAT1 HOTAIR H19 DAPK1 AFAP1-AS1
16 hepatocellular carcinoma 30.7 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTTIP
17 gastric cancer 30.7 UCA1 TMEM238L PVT1 MIR31HG MIR21 MALAT1
18 ovarian cancer 30.7 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTAIR
19 clear cell renal cell carcinoma 30.6 PVT1 MIR21 MALAT1
20 bladder cancer 30.5 UCA1 PVT1 MIR31HG MIR21 MALAT1 HOTAIR
21 colorectal cancer 30.3 UCA1 TMEM238L PVT1 MIR21 MIR155 MALAT1
22 breast cancer 30.2 UCA1 PVT1 MIR21 MIR155 MALAT1 LINC00339
23 adenocarcinoma 11.6
24 pancreatic adenocarcinoma 11.0
25 triple-receptor negative breast cancer 10.9 MALAT1 HOTAIR
26 ovarian epithelial cancer 10.9 MALAT1 HOTAIR H19
27 esophagus squamous cell carcinoma 10.9 HOTAIR AFAP1-AS1
28 polymyositis 10.8 MIR21 MIR155
29 lymphoma, hodgkin, classic 10.8 PVT1 MIR21 MIR155
30 laryngeal squamous cell carcinoma 10.8 MIR21 MALAT1 HOTAIR H19
31 gastric cardia adenocarcinoma 10.8 HOTAIR H19
32 malignant glioma 10.8 PVT1 HOTTIP HOTAIR
33 dermatomyositis 10.7 MIR21 MIR155
34 pancreatitis 10.7
35 astrocytoma 10.7 MIR21 LINC00339 HOTAIR H19
36 squamous cell carcinoma, head and neck 10.7 MIR21 MIR155 HOTAIR H19
37 diffuse large b-cell lymphoma 10.7 MIR21 MIR155 HOTAIR
38 esophagus adenocarcinoma 10.7 MIR21 AFAP1-AS1
39 tongue squamous cell carcinoma 10.7 UCA1 MIR21 MALAT1 HOTTIP AFAP1-AS1
40 pancreas disease 10.7
41 pancreatic ductal carcinoma 10.7
42 oral squamous cell carcinoma 10.7 UCA1 MIR21 MIR155 MALAT1 HOTAIR H19
43 pancreatic agenesis 1 10.6
44 myeloma, multiple 10.6 UCA1 PVT1 MALAT1 HOTAIR H19
45 microvascular complications of diabetes 3 10.6 PVT1 MALAT1
46 coronary heart disease 1 10.6 MIR155 HOTTIP H19
47 thyroid cancer, nonmedullary, 1 10.6 PVT1 MIR155 MALAT1 HOTTIP HOTAIR H19
48 autoimmune pancreatitis 10.6
49 rheumatoid arthritis 10.6 UCA1 MIR155 MALAT1 HOTAIR H19
50 severe combined immunodeficiency 10.6

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


abdominal pain, pruritus, icterus

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
2
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
3
leucovorin Approved Phase 3 58-05-9 143 6006
4
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
5
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
6 Adjuvants, Immunologic Phase 3
7 Viscosupplements Phase 3
8 Vitamin B9 Phase 3
9 Folate Phase 3
10 Hematinics Phase 3
11 Antidotes Phase 3
12 Vitamin B Complex Phase 3
13 Calcium, Dietary Phase 3
14
asparaginase Phase 3
15 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
16
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
17
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
19
Enoxaparin Approved Phase 2 9005-49-6 772
20
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
21
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
22
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
23
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
24
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
25
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
26
Propofol Approved, Investigational, Vet_approved Phase 2 2078-54-8 4943
27
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
28
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
29
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
30
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
31
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 60843 446556
32
Coal tar Approved Phase 1, Phase 2 8007-45-2
33
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
34
Pembrolizumab Approved Phase 2 1374853-91-4
35
Metformin Approved Phase 2 657-24-9 4091 14219
36
nivolumab Approved Phase 1, Phase 2 946414-94-4
37
Olaparib Approved Phase 2 763113-22-0 23725625
38
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
39
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
40
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
41
Durvalumab Approved, Investigational Phase 2 1428935-60-7
42
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
43
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
44
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
45
Cediranib Investigational Phase 2 288383-20-0 9933475
46 Misonidazole Investigational Phase 2 13551-87-6
47
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
48
Tremelimumab Investigational Phase 2 745013-59-6
49
Liposomal doxorubicin Phase 2 31703
50 Anti-Bacterial Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 204)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
3 A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03943667 Phase 3 Gemcitabine;Paclitaxel
4 Norwegian Pancreatic Cancer Trial (NorPACT) - 1: Norwegian Multicentre Un-blinded Phase III Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected Recruiting NCT02919787 Phase 2, Phase 3 Gemcitabine;5-FU;Capecitabine;Oxaliplatine;Irinotecan
5 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
6 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
7 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer During Pancreaticoduodenectomy (MAPLE-PD Trial) Not yet recruiting NCT03317886 Phase 3
8 A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma Not yet recruiting NCT03665441 Phase 3 eryaspase;Gemcitabine plus Abraxane;Irinotecan plus 5-FU plus leucovorin
9 Randomized Controlled Trial for the Evaluation of Complete Microscopic Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy (RAMPS) Not yet recruiting NCT03679169 Phase 3
10 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
11 Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer Unknown status NCT02124317 Phase 2 nanoparticle albumin-bound paclitaxel;S-1
12 Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer Unknown status NCT02135822 Phase 2 nanoparticle albumin-bound paclitaxel;gemcitabine
13 PHASE II Study - EFFICACY AND SAFETY OF PARPi TO TREAT PANCREATIC CANCER Unknown status NCT02511223 Phase 2 OLAPARIB
14 A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
15 A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
16 An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02981342 Phase 2 Abemaciclib;LY3023414;Gemcitabine;Capecitabine
17 A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
18 A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Completed NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
19 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2 Capecitabine;Oxaliplatin
20 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Completed NCT02440958 Phase 2 modified FOLFIRINOX regimen
21 Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT03529175 Phase 2 Abraxane (nab-paclitaxel);Gemcitabine
22 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
23 A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
24 A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20;Nab-paclitaxel;Gemcitabine;Dexamethasone;Enoxaparin
25 A Phase II Study of S-1 in Combination With Gemcitabine and Erlotinib in Patients With Advanced or Metastatic Pancreatic Cancer Completed NCT01693419 Phase 2 GES (Gemcitabine, Erlotinib, S-1)
26 A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed NCT01660711 Phase 2 5 Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin
27 A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03915444 Phase 2 nab-Paclitaxel + Cisplatin + Gemcitabine
28 A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03727880 Phase 2 Pembrolizumab;Defactinib
29 Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone Recruiting NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
30 Phase II Trial Comparing Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Patients With Advanced Pancreatic Cancer Recruiting NCT03636308 Phase 2 nanoparticle albumin-bound paclitaxel;S1;Gemcitabine
31 Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions Recruiting NCT03486327 Phase 2 BR55
32 A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection Recruiting NCT02178709 Phase 2 FOLFIRINOX
33 A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
34 A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03496662 Phase 1, Phase 2 BMS-813160;Nivolumab;Gemcitabine;Nab-paclitaxel
35 A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study). Recruiting NCT03806309 Phase 2 FOLFIRI;OSE2101;Nivolumab
36 A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRINOX Recruiting NCT04010552 Phase 2 NALRINOX combination
37 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040;Selicrelumab;Bevacizumab;Emactuzumab;RO6874281
38 Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
39 A Phase II Pilot Trial Of Paclitaxel Protein Bound and Gemcitabine Based Chemotherapy and the Addition Of Paricalcitol Upon Attainment of Stable or Progressive Disease in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT04054362 Phase 2 Paclitaxel protein bound;Cisplatin;Gemcitabine;Paricalcitol
40 Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2 Nab-paclitaxel and gemcitabine for R-PDAC Patients;Nab-paclitaxel and gemcitabine for BR-PDAC Patients
41 An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1 Recruiting NCT03525392 Phase 1, Phase 2 177Lu-3BP-227 (also called 177Lu-IPN01087)
42 A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy: An AIO Phase II Cross Over Trial (PANTHEON) Recruiting NCT03331640 Phase 2 OFF;FOLFIRI Protocol
43 Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer Recruiting NCT03977233 Phase 2 Oxaliplatin;Leucovorin;Irinotecan Hydrochloride;5-FU
44 Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer Recruiting NCT03498326 Phase 2 Gemcitabine;Gemcitabine
45 Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study Recruiting NCT02677038 Phase 2 Olaparib
46 Intraoperative Detection of Cancer Tissue in Pancreatic Adenocarcinoma Using a VEGF-targeted Optical Fluorescent Imaging Tracer, A Multicentre Feasibility Dose Escalation Study Recruiting NCT02743975 Phase 1, Phase 2 Bevacizumab-800CW
47 A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer Recruiting NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
48 A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03611556 Phase 1, Phase 2 gemcitabine;nab-paclitaxel
49 A Phase II Study of Pancreatic Enzyme Replacement (Zenpep) on Completion Rates of Adjuvant Chemotherapy Among Subjects With Resected Pancreatic Ductal Adenocarcinoma Recruiting NCT03469258 Phase 2 Pancrelipase
50 A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB IN COMBINATION WITH BINIMETINIB WITH OR WITHOUT TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS Recruiting NCT03637491 Phase 2 Avelumab;Binimetinib;Talazoparib

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

41
Pancreas, T Cells, Lymph Node, Liver, Neutrophil, Testes, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(show top 50) (show all 6949)
# Title Authors PMID Year
1
Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. 38 88
21088996 2011
2
MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. 38 88
21068491 2010
3
MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. 38 88
20093556 2010
4
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. 38 88
19723895 2009
5
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. 38 88
18719196 2008
6
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. 38 88
17237814 2007
7
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. 88
19551852 2010
8
Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma. 38
31435922 2020
9
Isolation and structural characterization of a pectin from Lycium ruthenicum Murr and its anti-pancreatic ductal adenocarcinoma cell activity. 38
31426957 2019
10
An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer. 38
30882895 2019
11
YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation. 38
31352078 2019
12
Cytopathology of anaplastic carcinoma of the pancreas: Review of a rare entity and description of a variant with signet ring cell features. 38
31254330 2019
13
Development and validation of a rapid and sensitive UPLC-MS/MS assay for simultaneous quantification of paclitaxel and cyclopamine in mouse whole blood and tissue samples. 38
30805953 2019
14
Pancreatic steatosis: an update. 38
31343416 2019
15
Predicting the Severity of Pancreatic Fistula after Pancreaticoduodenectomy: Overweight and Blood Loss as Independent Risk Factors: Retrospective Analysis of 277 Patients. 38
31063046 2019
16
Transforming growth factor beta-induced, an extracellular matrix interacting protein, enhances glycolysis and promotes pancreatic cancer cell migration. 38
30834519 2019
17
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. 38
31283563 2019
18
Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer. 38
31153980 2019
19
Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. 38
31199988 2019
20
Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. 38
31233838 2019
21
Immune-related somatic mutation genes are enriched in PDACs with diabetes. 38
31203147 2019
22
Expression of Monocarboxylate Transporter 1 Is Associated With Better Prognosis and Reduced Nodal Metastasis in Pancreatic Ductal Adenocarcinoma. 38
31404019 2019
23
Sulforaphane Induces miR135b-5p and Its Target Gene, RASAL2, thereby Inhibiting the Progression of Pancreatic Cancer. 38
31044154 2019
24
Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. 38
30801702 2019
25
Glucose metabolism during tumorigenesis in the genetic mouse model of pancreatic cancer. 38
30989379 2019
26
Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM). 38
31261289 2019
27
CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. 38
31243486 2019
28
Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. 38
31384459 2019
29
Application of the High-throughput TAB-Array for the Discovery of Novel 5-Hydroxymethylcytosine Biomarkers in Pancreatic Ductal Adenocarcinoma. 38
31413874 2019
30
Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. 38
28641032 2019
31
PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells. 38
31395860 2019
32
Genetic Ablation of the Cystine Transporter xCT in PDAC Cells Inhibits mTORC1, Growth, Survival, and Tumor Formation via Nutrient and Oxidative Stresses. 38
31175120 2019
33
Neoadjuvant chemotherapy with gemcitabine-based regimens improves the prognosis of node positive resectable pancreatic head cancer. 38
31281650 2019
34
Pancreatectomy with Hepatic Artery Resection for Pancreatic Head Cancer. 38
31396672 2019
35
Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. 38
31262731 2019
36
'Patchiness' and basic cancer research: unravelling the proteases. 38
31213124 2019
37
An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor. 38
31391296 2019
38
EGFR-Pak Signaling Selectively Regulates Glutamine Deprivation-Induced Macropinocytosis. 38
31257175 2019
39
Modeling Human Cancer-induced Cachexia. 38
31390573 2019
40
A Single-Cell Window into Pancreas Cancer Fibroblast Heterogeneity. 38
31371323 2019
41
Dissecting the presence of malignant squamous cells in pancreatic cytopathology: A case series. 38
31407529 2019
42
IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. 38
30927618 2019
43
Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. 38
30777697 2019
44
Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. 38
30412725 2019
45
ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. 38
31399545 2019
46
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. 38
31406261 2019
47
The Italian Rare Pancreatic Exocrine Cancer Initiative. 38
30967031 2019
48
Familial pancreatic adenocarcinoma: A retrospective analysis of germline genetic testing in a French multicentre cohort. 38
31432501 2019
49
Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. 38
31420046 2019
50
YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway. 38
31404611 2019

Variations for Pancreatic Ductal Adenocarcinoma

Copy number variations for Pancreatic Ductal Adenocarcinoma from CNVD:

7 (show top 50) (show all 315)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14616 1 109662726 110421733 Loss Pancreatic ductal adenocarcinoma
2 14979 1 111694621 112653686 Loss Pancreatic ductal adenocarcinoma
3 15141 1 11296895 11700048 Loss Pancreatic ductal adenocarcinoma
4 15254 1 113902673 114772618 Loss Pancreatic ductal adenocarcinoma
5 21071 1 156591077 157602759 Gain Pancreatic ductal adenocarcinoma
6 22927 1 16990962 17780550 Loss Pancreatic ductal adenocarcinoma
7 23665 1 172632928 173462394 Gain Pancreatic ductal adenocarcinoma
8 23983 1 174098656 174792564 Gain Pancreatic ductal adenocarcinoma
9 24268 1 17780550 18767187 Loss Pancreatic ductal adenocarcinoma
10 25340 1 18767187 19870518 Loss Pancreatic ductal adenocarcinoma
11 25429 1 189012940 189640525 Gain Pancreatic ductal adenocarcinoma
12 25525 1 190940606 191897513 Gain Pancreatic ductal adenocarcinoma
13 25603 1 191897513 192833019 Gain Pancreatic ductal adenocarcinoma
14 25668 1 192833019 193928417 Gain Pancreatic ductal adenocarcinoma
15 25957 1 195125528 196179631 Gain Pancreatic ductal adenocarcinoma
16 26123 1 197274194 198251428 Gain Pancreatic ductal adenocarcinoma
17 26286 1 19870518 21264484 Loss Pancreatic ductal adenocarcinoma
18 27649 1 210637543 211466127 Gain Pancreatic ductal adenocarcinoma
19 29512 1 232834654 234059648 Gain Pancreatic ductal adenocarcinoma
20 29988 1 23881482 24596143 Loss Pancreatic ductal adenocarcinoma
21 30783 1 24596143 24901021 Loss Pancreatic ductal adenocarcinoma
22 31049 1 24901021 26202341 Loss Pancreatic ductal adenocarcinoma
23 31229 1 26202341 27453508 Loss Pancreatic ductal adenocarcinoma
24 31475 1 27702974 28279739 Loss Pancreatic ductal adenocarcinoma
25 31649 1 29154418 29949616 Loss Pancreatic ductal adenocarcinoma
26 31710 1 29949616 31202941 Loss Pancreatic ductal adenocarcinoma
27 31822 1 31202941 32179980 Loss Pancreatic ductal adenocarcinoma
28 32104 1 33581730 34569385 Loss Pancreatic ductal adenocarcinoma
29 32211 1 34569385 35804738 Loss Pancreatic ductal adenocarcinoma
30 32498 1 36953732 37599763 Loss Pancreatic ductal adenocarcinoma
31 32649 1 38143717 38830556 Loss Pancreatic ductal adenocarcinoma
32 32759 1 3913633 5229374 Loss Pancreatic ductal adenocarcinoma
33 33297 1 44268667 45000776 Loss Pancreatic ductal adenocarcinoma
34 33745 1 47532872 48556325 Loss Pancreatic ductal adenocarcinoma
35 34094 1 5229374 6509870 Loss Pancreatic ductal adenocarcinoma
36 34199 1 53371440 53750907 Loss Pancreatic ductal adenocarcinoma
37 34230 1 53750907 54788971 Loss Pancreatic ductal adenocarcinoma
38 36948 1 8379388 9142502 Loss Pancreatic ductal adenocarcinoma
39 37455 1 9142502 9661749 Loss Pancreatic ductal adenocarcinoma
40 38508 10 103075332 103271952 Gain Pancreatic ductal adenocarcinoma
41 41307 10 15917593 17007248 Gain Pancreatic ductal adenocarcinoma
42 41728 10 22854210 23744923 Gain Pancreatic ductal adenocarcinoma
43 44446 10 57203760 58367659 Gain Pancreatic ductal adenocarcinoma
44 44911 10 64846281 66342495 Gain Pancreatic ductal adenocarcinoma
45 45553 10 72143312 73316160 Loss Pancreatic ductal adenocarcinoma
46 45655 10 73316160 74391172 Gain Pancreatic ductal adenocarcinoma
47 45775 10 74391172 75333936 Gain Pancreatic ductal adenocarcinoma
48 45937 10 75333936 76299818 Gain Pancreatic ductal adenocarcinoma
49 46231 10 79273961 80171344 Loss Pancreatic ductal adenocarcinoma
50 46288 10 80171344 81279277 Loss Pancreatic ductal adenocarcinoma

Expression for Pancreatic Ductal Adenocarcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Pancreatic Ductal Adenocarcinoma patients vs. healthy controls: 35 (show top 50) (show all 375)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SYCN syncollin Pancreas - 8.04 0.000
2 GP2 glycoprotein 2 (zymogen granule membrane) Pancreas - 7.99 0.000
3 ALB albumin Pancreas - 7.95 0.000
4 SERPINI2 serpin peptidase inhibitor, clade I (pancpin), member 2 Pancreas - 7.95 0.000
5 CELA2B chymotrypsin-like elastase family, member 2B Pancreas - 7.74 0.000
6 PNLIPRP1 pancreatic lipase-related protein 1 Pancreas - 7.66 0.000
7 PDIA2 protein disulfide isomerase family A, member 2 Pancreas - 7.53 0.000
8 SPX spexin hormone Pancreas - 7.53 0.000
9 CTRL chymotrypsin-like Pancreas - 7.52 0.000
10 COL10A1 collagen, type X, alpha 1 Pancreas + 7.52 0.000
11 CELP carboxyl ester lipase pseudogene Pancreas - 7.50 0.000
12 COL5A1 collagen, type V, alpha 1 Pancreas + 7.46 0.000
13 SULF1 sulfatase 1 Pancreas + 7.38 0.000
14 CUZD1 CUB and zona pellucida-like domains 1 Pancreas - 7.29 0.000
15 POSTN periostin, osteoblast specific factor Pancreas + 7.24 0.000
16 COL1A1 collagen, type I, alpha 1 Pancreas + 7.17 0.000
17 AQP8 aquaporin 8 Pancreas - 7.14 0.000
18 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 Pancreas + 7.10 0.000
19 COL11A1 collagen, type XI, alpha 1 Pancreas + 7.00 0.000
20 CLPS colipase, pancreatic Pancreas - 6.99 0.000
21 INHBA inhibin, beta A Pancreas + 6.95 0.000
22 CPA2 carboxypeptidase A2 (pancreatic) Pancreas - 6.88 0.000
23 CTRC chymotrypsin C (caldecrin) Pancreas - 6.87 0.000
24 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Pancreas + 6.86 0.000
25 PLA2G1B phospholipase A2, group IB (pancreas) Pancreas - 6.79 0.001
26 COL3A1 collagen, type III, alpha 1 Pancreas + 6.78 0.000
27 SFRP4 secreted frizzled-related protein 4 Pancreas + 6.76 0.000
28 CELA3A chymotrypsin-like elastase family, member 3A Pancreas - 6.76 0.001
29 GNMT glycine N-methyltransferase Pancreas - 6.74 0.000
30 COL1A2 collagen, type I, alpha 2 Pancreas + 6.72 0.000
31 REG1P regenerating islet-derived 1 pseudogene Pancreas - 6.72 0.000
32 S100P S100 calcium binding protein P Pancreas + 6.67 0.000
33 CELA3B chymotrypsin-like elastase family, member 3B Pancreas - 6.66 0.001
34 CEL carboxyl ester lipase Pancreas - 6.63 0.001
35 CTHRC1 collagen triple helix repeat containing 1 Pancreas + 6.60 0.000
36 CPA1 carboxypeptidase A1 (pancreatic) Pancreas - 6.56 0.001
37 VCAN versican Pancreas + 6.51 0.000
38 TMEM52 transmembrane protein 52 Pancreas - 6.40 0.000
39 REG1B regenerating islet-derived 1 beta Pancreas - 6.35 0.002
40 CTSE cathepsin E Pancreas + 6.30 0.000
41 GLS2 glutaminase 2 (liver, mitochondrial) Pancreas - 6.28 0.000
42 KLK1 kallikrein 1 Pancreas - 6.26 0.000
43 GJB2 gap junction protein, beta 2, 26kDa Pancreas + 6.24 0.000
44 REG3G regenerating islet-derived 3 gamma Pancreas - 6.17 0.000
45 PLAU plasminogen activator, urokinase Pancreas + 6.15 0.000
46 COL5A2 collagen, type V, alpha 2 Pancreas + 6.13 0.000
47 SLC39A5 solute carrier family 39 (zinc transporter), member 5 Pancreas - 6.09 0.000
48 ERP27 endoplasmic reticulum protein 27 Pancreas - 6.07 0.000
49 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C Pancreas + 6.00 0.000
50 PNLIP pancreatic lipase Pancreas - 5.94 0.004
Search GEO for disease gene expression data for Pancreatic Ductal Adenocarcinoma.

Pathways for Pancreatic Ductal Adenocarcinoma

Pathways related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 UCA1 HOTAIR

GO Terms for Pancreatic Ductal Adenocarcinoma

Biological processes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of activated T cell proliferation GO:0042104 9.16 MIR21 MIR155
2 positive regulation of cardiac muscle hypertrophy GO:0010613 8.96 MIR21 MIR155
3 negative regulation of regulatory T cell differentiation GO:0045590 8.62 MIR21 MIR155

Sources for Pancreatic Ductal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....